drugset
drugset / Trial / NCT00768937

Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma

NCT00768937 ↗

Phase 1/2 Completed 22 enrolled Medical University of Vienna
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Hepatocellular carcinoma (HCC) as the third most common cause of cancer-related death has a very poor prognosis. Aim of this open label single arm non randomized pilot trial is the evaluation of the efficacy and safety of sorafenib in combination with TACE in patients with unresectable HCC. Efficacy ad safety will be compared with a historical TACE-only group of a placebo controlled TACE-trial.

Timeline

Start
2008-09
Primary completion
2010-10
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule 800 mg Oral

Indications

hepatocellular carcinoma